$0.99
8.79% today
Nasdaq, Nov 20, 10:18 pm CET
ISIN
US57055L1070
Symbol
MRKR

Marker Therapeutics, Inc. Stock price

$1.09
+0.06 5.83% 1M
-0.04 3.54% 6M
-2.02 64.95% YTD
-2.10 65.83% 1Y
-2.21 66.98% 3Y
-13.81 92.68% 5Y
-79.21 98.64% 10Y
+0.97 808.33% 20Y
Nasdaq, Closing price Wed, Nov 19 2025
+0.08 7.92%
ISIN
US57055L1070
Symbol
MRKR
Industry

Key metrics

Basic
Market capitalization
$18.2m
Enterprise Value
$7.7m
Net debt
positive
Cash
$10.5m
Shares outstanding
11.3m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
3.4 | -
EV/Sales
1.4 | -
EV/FCF
negative
P/B
1.7
Financial Health
Equity Ratio
84.3%
Return on Equity
-57.8%
ROCE
-139.9%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$5.4m | $2.7m
EBITDA
- | $-15.5m
EBIT
$-14.7m | $-26.1m
Net Income
$-14.6m | $-21.2m
Free Cash Flow
$-10.9m
Growth (TTM | estimate)
Revenue
44.5% | -59.0%
EBITDA
- | -
EBIT
-33.5% | -134.5%
Net Income
-40.9% | -97.7%
Free Cash Flow
0.1%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -574.0%
EBIT
-272.4%
Net
-271.1% | -784.0%
Free Cash Flow
-202.1%
More
EPS
$-1.0
FCF per Share
$-1.0
Short interest
8.0%
Employees
5
Rev per Employee
$1.3m
Show more

Is Marker Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,048 stocks worldwide.

Marker Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Marker Therapeutics, Inc. forecast:

8x Buy
89%
1x Hold
11%

Analyst Opinions

9 Analysts have issued a Marker Therapeutics, Inc. forecast:

Buy
89%
Hold
11%

Financial data from Marker Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
5.39 5.39
45% 45%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 4.19 4.19
19% 19%
78%
- Research and Development Expense 16 16
66% 66%
294%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -15 -15
33% 33%
-272%
Net Profit -15 -15
41% 41%
-271%

In millions USD.

Don't miss a Thing! We will send you all news about Marker Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Marker Therapeutics, Inc. Stock News

Neutral
GlobeNewsWire
6 days ago
APOLLO study showed encouraging overall responses and favorable safety profile in relapsed/refractory B-cell lymphoma
Neutral
GlobeNewsWire
15 days ago
HOUSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced the appointment of Kathryn Penkus Corzo, R.Ph., MBA to the Company's Board of Directors, effective November 1,...
Neutral
GlobeNewsWire
17 days ago
Ongoing Phase 1 APOLLO study investigating MT-601 in patients with relapsed B cell lymphomas showed encouraging preliminary efficacy data
More Marker Therapeutics, Inc. News

Company Profile

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company, which specializes in the development and commercialization of novel cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company was founded on October 22, 1991 and is headquartered in Houston, TX.

Head office United States
CEO Juan Vera
Employees 5
Founded 1991
Website markertherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today